Chinese Journal of Antituberculosis ›› 2022, Vol. 44 ›› Issue (9): 960-965.doi: 10.19982/j.issn.1000-6621.20220236
• Review Articles • Previous Articles Next Articles
Chen Qiuqi1, Han Tingting1, Wang Qingwen2, Deng Guofang3()
Received:
2022-06-21
Online:
2022-09-10
Published:
2022-09-05
Contact:
Deng Guofang
E-mail:jxxk1035@yeah.net
Supported by:
CLC Number:
Chen Qiuqi, Han Tingting, Wang Qingwen, Deng Guofang. Recent advances in treatment of latent tuberculosis infection complicated with rheumatic diseases[J]. Chinese Journal of Antituberculosis, 2022, 44(9): 960-965. doi: 10.19982/j.issn.1000-6621.20220236
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.zgflzz.cn/EN/10.19982/j.issn.1000-6621.20220236
[1] |
Miltinienė D, Deresevicˇienė G, Nakcˇerienė B, et al. Incidence of Tuberculosis in Inflammatory Rheumatic Diseases: Results from a Lithuanian Retrospective Cohort Study. Medicina (Kaunas), 2020, 56(8):392. doi: 10.3390/medicina56080392.
doi: 10.3390/medicina56080392 |
[2] |
Rotar Z, Svetina P, Tomsic M, et al. Tuberculosis among patients treated with TNF inhibitors for rheumatoid arthritis,ankylosing spondylitis and psoriatic arthritis in Slovenia:a cohort study. BMJ Open, 2020, 10(2):e034356. doi: 10.1136/bmjopen-2019-034356.
doi: 10.1136/bmjopen-2019-034356 URL |
[3] |
潘艳艳, 吴园园, 蔡红娇, 等. 不同的风湿免疫性疾病患者免疫功能差异分析. 当代医学, 2020, 26(19):1-4. doi: 10.3969/j.issn.1009-4393.2020.19.001.
doi: 10.3969/j.issn.1009-4393.2020.19.001 |
[4] |
Dolff S, Quandt D, Feldkamp T, et al. Increased percentages of PD-1 on CD4+ T cells is associated with higher INF-γ production and altered IL-17 production in patients with systemic lupus erythematosus. Scand J Rheumatol, 2014, 43(4):307-313. doi: 10.3109/03009742.2013. 869830.
doi: 10.3109/03009742.2013.869830 pmid: 25088926 |
[5] |
Anton C, Machado FD, Ramirez JMA, et al. Latent tuberculosis infection in patients with rheumatic diseases. J Bras Pneumol, 2019, 45(2):e20190023. doi: 10.1590/1806-3713/e201 90023.
doi: 10.1590/1806-3713/e201 90023 |
[6] |
Scrivo R, Armignacco O. Tuberculosis risk and anti-tumour necrosis factor agents in rheumatoid arthritis: a critical appraisal of national registry data. Int J Rheum Dis, 2014, 17(7):716-724. doi: 10.1111/1756-185X.12375.
doi: 10.1111/1756-185X.12375 URL |
[7] |
Ehlers S. Role of tumour necrosis factor (TNF) in host defence against tuberculosis: implications for immunotherapies targeting TNF. Ann Rheum Dis, 2003, 62 Suppl 2:ii37-42. doi: 10.1136/ard.62.suppl_2.ii37.
doi: 10.1136/ard.62.suppl_2.ii37 pmid: 14532147 |
[8] |
Robert M, Miossec P. Reactivation of latent tuberculosis with TNF inhibitors: critical role of the beta 2 chain of the IL-12 receptor. Cell Mol Immunol, 2021, 18(7):1644-1651. doi: 10.1038/s41423-021-00694-9.
doi: 10.1038/s41423-021-00694-9 pmid: 34021269 |
[9] |
Garziera G, Morsch ALB, Otesbelgue F, et al. Latent tuberculosis infection and tuberculosis in patients with rheumatic diseases treated with anti-tumor necrosis factor agents. Clin Rheumatol, 2017, 36(8):1891-1896. doi: 10.1007/s10067-017-3714-6.
doi: 10.1007/s10067-017-3714-6 pmid: 28589321 |
[10] |
Long W, Cai F, Wang X, et al. High risk of activation of latent tuberculosis infection in rheumatic disease patients. Infect Dis (Lond), 2020, 52(2):80-86. doi: 10.1080/23744235.2019.1682187.
doi: 10.1080/23744235.2019.1682187 |
[11] |
Pettipher C, Benitha R. Tuberculosis in biologic users for rheumatic diseases: results from the South African Biologics Registry (SABIO). Ann Rheum Dis, 2020, 79(2):292-299. doi: 10.1136/annrheumdis-2019-216128.
doi: 10.1136/annrheumdis-2019-216128 pmid: 31791950 |
[12] |
Malaviya AN, Aggarwal VK, Rawat R, et al. Screening for latent tuberculosis infection among patients with rheumatoid arthritis in the era of biologics and targeted synthetic disease-modifying anti-rheumatic drugs in India, a high-burden TB country: The importance of Mantoux and Quantiferon-TB Gold tests. Int J Rheum Dis, 2018, 21(8):1563-1571. doi: 10.1111/1756-185X.13261.
doi: 10.1111/1756-185X.13261 pmid: 29345081 |
[13] |
Lee J, Kim E, Jang EJ, et al. Efficacy of Treatment for Latent Tuberculosis in Patients Undergoing Treatment with a Tumor Necrosis Factor Antagonist. Ann Am Thorac Soc, 2017, 14(5):690-697. doi: 10.1513/AnnalsATS.201608-647OC.
doi: 10.1513/AnnalsATS.201608-647OC URL |
[14] |
Cuomo G, D’Abrosca V, Iacono D, et al. The conversion rate of tuberculosis screening tests during biological therapies in patients with rheumatoid arthritis. Clin Rheumatol, 2017, 36(2):457-461. doi: 10.1007/s10067-016-3462-z.
doi: 10.1007/s10067-016-3462-z URL |
[15] |
中国医学科学院病原生物学研究所, 中国疾病预防控制中心,中国科学院地理科学与资源研究所. 全国结核分枝杆菌潜伏感染率估算专家共识. 中国防痨杂志, 2022, 44(1):4-8. doi: 10.19982/j.issn.1000-6621.20210662.
doi: 10.19982/j.issn.1000-6621.20210662 |
[16] |
邱可为, 郭欣, 黄启当, 等. T细胞酶联免疫斑点法对风湿病患者感染结核分支杆菌的诊断价值. 临床医学工程, 2016, 23(9):1184-1186. doi: 10.3969/j.issn.1674-4659.2016.09.1184.
doi: 10.3969/j.issn.1674-4659.2016.09.1184 |
[17] |
黄安芳, 罗妍, 赵毅, 等. 风湿病患者合并潜伏性结核感染的分析. 中华内科杂志, 2016, 55(4):307-310. doi: 10.3760/cma.j.issn.0578-1426.2016.04.012.
doi: 10.3760/cma.j.issn.0578-1426.2016.04.012 |
[18] |
邓国防, 王玉香, 陈涛, 等. 风湿免疫性疾病并发结核感染的临床特征分析. 中国防痨杂志, 2018, 40(4):392-396. doi: 10.3969/j.issn.1000-6621.2018.04.009.
doi: 10.3969/j.issn.1000-6621.2018.04.009 |
[19] |
朱翠云. 对人类免疫缺陷病毒感染者潜伏性结核感染的筛查和干预. 上海医药, 2020, 41(11):14-16,20. doi: 10.3969/j.issn.1006-1533.2020.11.005.
doi: 10.3969/j.issn.1006-1533.2020.11.005 |
[20] | Lloyd N, Martin D, Peter DOD. Clinical Tuberculosis-Sixth Edition. CRC Press, 2020:154. |
[21] |
中国防痨协会, 中国防痨协会学校与儿童结核病防治专业分会,《中国防痨杂志》编辑委员会. 重组结核杆菌融合蛋白(EC)临床应用专家共识. 中国防痨杂志, 2020, 42(8):761-768. doi: 10.3969/i.issn.1000-6621.2020.08.001.
doi: 10.3969/i.issn.1000-6621.2020.08.001 |
[22] |
Pai M, Zwerling A, Menzies D. Systematic review: T-cell-based assays for the diagnosis of latent tuberculosis infection: an update. Ann Intern Med, 2008, 149(3):177-184. doi: 10.7326/0003-4819-149-3-200808050-00241.
doi: 10.7326/0003-4819-149-3-200808050-00241 URL |
[23] |
Metcalfe JZ, Everett CK, Steingart KR, et al. Interferon-γ release assays for active pulmonary tuberculosis diagnosis in adults in low- and middle-income countries: systematic review and meta-analysis. J Infect Dis, 2011, 204 Suppl 4:S1120-1129. doi: 10.1093/infdis/jir410.
doi: 10.1093/infdis/jir410 |
[24] |
赵静, 刘轩, 沈广萍, 等. T-SPOT. TB对风湿免疫病患者活动性肺结核诊断准确性的影响因素分析. 国际检验医学杂志, 2020, 41(7):850-855. doi: 10.3969/j.issn.1673-4130.2020.07.019.
doi: 10.3969/j.issn.1673-4130.2020.07.019 |
[25] |
许敏殷, 刘银, 刘丽蓉, 等. γ干扰素释放试验联合IL-6检测对活动性肺结核的诊断价值. 中国现代医学杂志, 2020, 30(10):18-21. doi: 10.3969/j.issn.1005-8982.2020.10.004.
doi: 10.3969/j.issn.1005-8982.2020.10.004 |
[26] |
Wang PH, Lin CH, Chang TH, et al. Chest roentgenography is complementary to interferon-gamma release assay in latent tuberculosis infection screening of rheumatic patients. BMC Pulm Med, 2020, 20(1):232. doi: 10.1186/s12890-020-01274-9.
doi: 10.1186/s12890-020-01274-9 URL |
[27] |
Chung TT, Ko HJ, Lau CS, et al. A retrospective study on the risk of tuberculosis in patients with rheumatoid arthritis. Rheumatol Int, 2020, 40(6):983-990. doi: 10.1007/s00296-020-04583-8.
doi: 10.1007/s00296-020-04583-8 pmid: 32318800 |
[28] |
Ciang NC, Chan SCW, Lau CS, et al. Risk of tuberculosis in patients with spondyloarthritis:data from a centralized electronic database in Hong Kong. BMC Musculoskelet Disord, 2020, 21(1):832. doi: 10.1186/s12891-020-03855-5.
doi: 10.1186/s12891-020-03855-5 URL |
[29] |
Dey M, Zhao SS, Moots RJ. Anti-TNF biosimilars in rheumatology:the end of an era? Expert Opin Biol Ther, 2021, 21(1):29-36. doi: 10.1080/14712598.2020.1802421.
doi: 10.1080/14712598.2020.1802421 URL |
[30] |
Evangelatos G, Koulouri V, Iliopoulos A, et al. Tuberculosis and targeted synthetic or biologic DMARDs, beyond tumor necrosis factor inhibitors. Ther Adv Musculoskelet Dis, 2020, 12:1759720X20930116. doi: 10.1177/1759720X20930116.
doi: 10.1177/1759720X20930116 |
[31] |
Goel N, Torralba K, Downey C, et al. Screening for acquired latent tuberculosis in rheumatoid arthritis patients on tumor necrosis factor inhibition therapy in Southern California. Clin Rheumatol, 2020, 39(8):2291-2297. doi: 10.1007/s10067-020-04991-y.
doi: 10.1007/s10067-020-04991-y URL |
[32] |
Yu CL, Yang CH, Chi CC. Drug Survival of Biologics in Treating Ankylosing Spondylitis:A Systematic Review and Meta-analysis of Real-World Evidence. BioDrugs, 2020, 34(5):669-679. doi: 10.1007/s40259-020-00442-x.
doi: 10.1007/s40259-020-00442-x URL |
[33] |
Chiu YM, Chen DY. Infection risk in patients undergoing treatment for inflammatory arthritis:non-biologics versus biologics. Expert Rev Clin Immunol, 2020, 16(2):207-228. doi: 10.1080/1744666X.2019.1705785.
doi: 10.1080/1744666X.2019.1705785 URL |
[34] |
Elewski BE, Baddley JW, Deodhar AA, et al. Association of Secukinumab Treatment With Tuberculosis Reactivation in Patients With Psoriasis,Psoriatic Arthritis,or Ankylosing Spondylitis. JAMA Dermatol, 2021, 157(1):43-51. doi: 10.1001/jamadermatol.2020.3257.
doi: 10.1001/jamadermatol.2020.3257 URL |
[35] |
Cantini F, Blandizzi C, Niccoli L, et al. Systematic review on tuberculosis risk in patients with rheumatoid arthritis receiving inhibitors of Janus Kinases. Expert Opin Drug Saf, 2020, 19(7):861-872. doi: 10.1080/14740338.2020.1774550.
doi: 10.1080/14740338.2020.1774550 URL |
[36] |
Cantini F, Niccoli L, Capone A, et al. Risk of tuberculosis reactivation associated with traditional disease modifying anti-rheumatic drugs and non-anti-tumor necrosis factor biologics in patients with rheumatic disorders and suggestion for clinical practice. Expert Opin Drug Saf, 2019, 18(5):415-425. doi: 10.1080/14740338.2019.1612872.
doi: 10.1080/14740338.2019.1612872 URL |
[37] |
Singh S, Singh S. JAK-STAT inhibitors: Immersing therapeutic approach for management of rheumatoid arthritis. Int Immunopharmacol, 2020, 86:106731. doi: 10.1016/j.intimp.2020.106731.
doi: 10.1016/j.intimp.2020.106731 URL |
[38] |
Angelini J, Talotta R, Roncato R, et al. JAK-Inhibitors for the Treatment of Rheumatoid Arthritis:A Focus on the Present and an Outlook on the Future. Biomolecules, 2020, 10(7):1002. doi: 10.3390/biom10071002.
doi: 10.3390/biom10071002 URL |
[39] | 辉瑞公司. 枸橼酸托托法替布片说明书. [2022.04.28]. https://labeling.pfizer.com/ShowLabeling.aspx?id=14493. |
[40] |
Mohamed DF, Habeeb RA, Hosny SM, et al. Incidence and risk of infection in egyptian patients with systemic lupus erythematosus. Clin Med Insights Arthritis Musculoskelet Disord, 2014, 7:41-48. doi: 10.4137/CMAMD.S15346.
doi: 10.4137/CMAMD.S15346 |
[41] |
Lao M, Chen D, Wu X, et al. Active tuberculosis in patients with systemic lupus erythematosus from Southern China: a retrospective study. Clin Rheumatol, 2019, 38(2):535-543. doi: 10.1007/s10067-018-4303-z.
doi: 10.1007/s10067-018-4303-z URL |
[42] |
Lorenzetti R, Zullo A, Ridola L, et al. Higher risk of tuberculosis reactivation when anti-TNF is combined with immunosuppressive agents:a systematic review of randomized controlled trials. Ann Med, 2014, 46(7):547-554. doi: 10.3109/07853890.2014.941919.
doi: 10.3109/07853890.2014.941919 pmid: 25105206 |
[43] |
Alaşan F, Güleç Balbay E, Cangür Ş, et al. Should isoniazid prophylaxis be prescribed to the patients under tumor necrosis factor-alpha antagonists independent of tuberculin skin test?. Aging Male, 2020, 23(5):1109-1114. doi: 10.1080/13685538.2019.1678582.
doi: 10.1080/13685538.2019.1678582 URL |
[44] | World Health Organization. Latent tuberculosis infection-Updated and consolidated guidelines for programmatic management. Geneva: World Health Organization, 2018. |
[45] |
Sterling TR, Njie G, Zenner D, et al. Guidelines for the Treatment of Latent Tuberculosis Infection: Recommendations from the National Tuberculosis Controllers Association and CDC, 2020. MMWR Recomm Rep, 2020, 69(1):1-11. doi: 10.15585/mmwr.rr6901a1.
doi: 10.15585/mmwr.rr6901a1 |
[46] |
Tang P, Johnston J. Treatment of Latent Tuberculosis Infection. Curr Treat Options Infect Dis, 2017, 9(4):371-379. doi: 10.1007/s40506-017-0135-7.
doi: 10.1007/s40506-017-0135-7 URL |
[47] |
Hong Kong Chest Service, Tuberculosis Research Centre, Madras/British Medical Research Council. A double-blind placebo-controlled clinical trial of three antituberculosis chemoprophylaxis regimens in patients with silicosis in Hong Kong. Hong Kong Chest Service/Tuberculosis Research Centre, Madras/British Medical Research Council. Am Rev Respir Dis, 1992, 145(1):36-41. doi: 10.1164/ajrccm/145.1.36.
doi: 10.1164/ajrccm/145.1.36 URL |
[48] |
Njie GJ, Morris SB, Woodruff RY, et al. Isoniazid-Rifapentine for Latent Tuberculosis Infection: A Systematic Review and Meta-analysis. Am J Prev Med, 2018, 55(2):244-252. doi: 10.1016/j.amepre.2018.04.030.
doi: 10.1016/j.amepre.2018.04.030 URL |
[49] |
Menzies D, Trajman A. New short regimens for latent tuberculosis treatment:safety first!. Eur Respir J, 2018, 52(6):1802180. doi: 10.1183/13993003.02180-2018.
doi: 10.1183/13993003.02180-2018 |
[50] | World Health Organization. WHO operational handbook on tuberculosis (Module 1-Prevention): Tuberculosis preventive treatment. Geneva: World Health Organization, 2020. |
[1] | Tuberculosis Control Branch of Chinese Antituberculosis Association, The Youth Branch of Chinese Antituberculosis Association, Editorial Board of Chinese Journal of Antituberculosis. Evidence-based guidelines for application of digital adherence technology in tuberculosis medication management in China [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 385-397. |
[2] | Li Jinhao, Hu Dongmei, Xu Caihong. Investigation on the willingness of tuberculosis health-care workers to implement tuberculosis preventive treatment and analysis of influencing factors [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 398-407. |
[3] | Li Yuhong, Mei Jinzhou, Su Wei, Ruan Yunzhou, Liu Yushu, Zhao Yanlin, Liu Xiaoqiu. Analysis of the treatment outcomes and influencing factors of rifampicin-resistant pulmonary tuberculosis patients aged 65 and above in China from 2015 to 2021 [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 408-415. |
[4] | Jiang Xue, Bai Yunlong, Ma Jianjun, An Yuan, Yang Fan, Zhao Qinglong. Status and influencing factors of diagnosis and treatment delay of rifampicin resistant pulmonary tuberculosis patients, Jilin Province, 2020—2023 [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 416-424. |
[5] | Wu Xuan, Zhang Yanqiu, Xu Jiying, Meng Dan, Sun Dingyong. Analysis of factors influencing the treatment outcomes of patients with pulmonary tuberculosis and diabetes mellitus in Henan Province (2019—2023) [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 425-431. |
[6] | An Yuan, Bai Yunlong, Zhao Qinglong, Ma Jianjun, Jiang Xue, Pan Yan, Gao Ying, Gao Zhihui. Analysis of treatment outcomes and influencing factors of patients with pulmonary tuberculosis complicated with diabetes mellitus in Jilin Province,2018—2022 [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 432-438. |
[7] | Feng Wei, Zheng Hailun, Meng Weili, Luo Ping. Analysis of under-reporting before arrival of pulmonary tuberculosis patients registered and managed by Tuberculosis Prevention and Control Institutions in Xicheng District, Beijing from 2018 to 2023 [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 439-443. |
[8] | Hu Yifan, Du Boping, Wu Yadong, Zhu Chuanzhi, Zhang Lanyue, Jia Hongyan, Sun Qi, Pan Liping, Zhang Zongde, Li Zihui. Experimental study on the role of Mce4C in the uptake and utilization of cholesterol by Mycobacterium tuberculosis [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 444-453. |
[9] | Sheng Jie, Hong Kaifeng, Mierzhati Aisha, Tang Wei, Dilixiati Abulizi. Study on the mechanism of IL-22 and p38 MAPK signaling pathways in inhibiting bone destruction in bone and joint tuberculosis [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 454-459. |
[10] | Wang Yingchao, Liu Weiyi, Ji Xiuxiu, Shang Xuetian, Jia Hongyan, Zhang Lanyue, Sun Qi, Du Boping, Zhu Chuanzhi, Pan Liping, Zhang Zongde. Profile analysis of circRNA expression and identification of diagnostic markers in peripheral blood mononuclear cells of tuberculosis patients [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 460-470. |
[11] | Zhu Mingzhi, Shao Yanqin, Fan Dapeng, Liu Libin, Mei Bin, Dai Lingshan, Cai Long. Diagnostic value of urine lipoarabinomannan antigen detection in extrapulmonary tuberculosis [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 471-476. |
[12] | Hao Mingxiao, Mi Jie, Xu Zongyi. Effectiveness of a continuity of care model in patients with tuberculous meningitis [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 477-481. |
[13] | Shang Xiyu, Zhang Huifang, Cao Yuqing, Xiong Yibai, Ji Xinyu, Tian Yaxin, Li Jiajia, Wang Ni, Ma Yan. Bibliometric analysis of global research status and hotspots in the basic research of Traditional Chinese Medicine for tuberculosis [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 482-497. |
[14] | Qin Lili, Yang Chengqing, Mai Hongzhen, Xu Qifeng, Xue Xinying, Lu Xiwei. Advances in the clinical diagnosis and treatment of post-tuberculosis chronic pulmonary aspergillosis [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 498-504. |
[15] | Luo Li, Luo Linzi, Yin Quhua, Zhou Lei, Lu Zhibin, Ding Yan, Xiao Yangbao. Progress in bronchoscopic diagnosis and treatment of lymph node fistula tracheobronchial tuberculosis [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 505-512. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||